Keyword: Bristol-Myers Squibb
New data suggest immunotherapy could stall mesothelioma—and that when it comes to Bristol-Myers' checkpoint inhibitors, two might be better than one.
With gaping holes in its portfolio, some analysts worry that Novartis CEO Joe Jimenez might take cash from expected asset sales to do a megadeal.
Pfizer and Bristol-Myers face three new lawsuits in New York claiming their big-selling anticoagulant Eliquis ended up hurting patients.
In the immuno-oncology rivalry between Merck’s Keytruda and BMS’ Opdivo, Keytruda has been running the table. But Opdivo boasts the latest win.
It’s good to be Merck these days. Less than a week after Keytruda nabbed an FDA go-ahead in bladder cancer, it scored a speedy review in stomach cancer.
So much has happened in the immuno-oncology field over the last two weeks that, frankly, we at FiercePharma aren’t sure we even recognize it anymore.
Reeling from multiple court defeats in litigation linking its talc products to ovarian cancer, Johnson & Johnson is taking its arguments to appeals court.
Your move, Bristol-Myers Squibb and AstraZeneca. Merck’s Keytruda-chemo combo has its first-line lung cancer approval.
Roche’s Tecentriq wasn’t supposed to fail its phase 3 trial in second-line bladder cancer. But it did—and that may mean trouble for other checkpoint inhibitors.
A judge in New York tossed liability claims against Pfizer and Bristol-Myers Squibb over bleeding risks for their blockbuster anticoagulant Eliquis.